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Abstract
Background—Acute decompensated heart failure (ADHF) is a leading cause of hospitalization 
in older persons in the United States. Reduced physical function and frailty are major determinants 
of adverse outcomes in older patients with hospitalized ADHF. However, these are not addressed 
by current heart failure (HF) management strategies and there has been little study of exercise 
training in older, frail HF patients with recent ADHF.
Hypothesis—Targeting physical frailty with a multi-domain structured physical rehabilitation 
intervention will improve physical function and reduce adverse outcomes among older patients 
experiencing a HF hospitalization.
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Study Design—Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) is a 
multi-center clinical trial in which 360 patients ≥ 60 years hospitalized with ADHF will be 
randomized either to a novel 12-week multi-domain physical rehabilitation intervention or to 
attention control. The goal of the intervention is to improve balance, mobility, strength and 
endurance utilizing reproducible, targeted exercises administered by a multi-disciplinary team with 
specific milestones for progression. The primary study aim is to assess the efficacy of the 
REHAB-HF intervention on physical function measured by total Short Physical Performance 
Battery score. The secondary outcome is 6-month all-cause rehospitalization. Additional outcome 
measures include quality of life and costs.
Conclusions—REHAB-HF is the first randomized trial of a physical function intervention in 
older patients with hospitalized ADHF designed to determine if addressing deficits in balance, 
mobility, strength and endurance improves physical function and reduces rehospitalizations. It will 
address key evidence gaps concerning the role of physical rehabilitation in the care of older 
patients, those with ADHF, frailty, and multiple comorbidities.
Keywords
Heart Failure; Physical rehabilitation; Frailty; Hospitalization
Introduction
Acute decompensated heart failure (ADHF) is a leading cause of hospitalization in older 
persons in the United States.1 Hospitalized ADHF is associated with severely reduced 
health-related quality of life (QOL), persistently high rehospitalization rates,2 markedly 
increased mortality,3 and costs over $16 billion per year in the United States.4 Despite 
advances in the treatment of chronic heart failure with reduced ejection fraction (HFrEF), 
there has been relatively little progress with respect to ADHF therapies. Current heart failure 
(HF) management guidelines, even when perfectly adhered to, have had only modest impact 
on ADHF outcomes, particularly rehospitalizations in the older population.2, 5 Furthermore, 
several recent trials of new interventions to improve ADHF outcomes, such as remote 
monitoring,6, 7 alternative diuretic regimens,8 novel pharmacologic agents9, 10 and 
biomarker guidance11 have not proven beneficial. The typical older ADHF patient has >5 
comorbidities that contribute to adverse outcomes.5, 12–14 Frequent non-cardiac 
comorbidities may explain the unexpected finding from multiple studies that >50% of 
rehospitalizations in older ADHF patients are due to non-cardiac events rather than recurrent 
ADHF.3, 5, 12, 15
Multiple lines of evidence suggest that severely reduced physical function and frailty are 
major determinants of adverse outcomes in older patients with hospitalized ADHF.16 We 
and others have shown that even when stable with compensated cardiovascular function, 
older patients with chronic HF have severe impairments in physical function due to the 
combined effects of aging, cardiovascular dysfunction, and impaired skeletal muscle 
function.17–19 As patients with chronic HF transition to ADHF, physical function worsens 
both because of HF decompensation and accelerated physical deconditioning.20, 21 This is 
further exacerbated by the hospital processes, including bed rest which can markedly 
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exacerbate physical dysfunction and acute muscle loss,20, 22, 23 contributing to what has now 
been termed the ‘post-hospital syndrome’.24
After resolution of the acute HF symptoms and congestion, older ADHF patients continue to 
have marked impairments in physical function, including deficits in strength, balance, 
mobility and endurance, and most patients meet formal definitions of frailty.20, 25 
Furthermore, these deficits persist and some patients never recover baseline 
function.24, 26, 27 This occurs during the most vulnerable, high risk period for 
rehospitalization and adverse outcomes, up to 6 months post discharge,3 and likely 
contribute to the high costs of rehospitalizations. These costs are now targeted by the 
Centers for Medicare & Medicaid Services (CMS) penalties reducing payments to hospitals 
with excess readmissions.28
Prior clinical trials of exercise training in HF (n>40), including those used to support the 
decision by CMS to expand cardiac rehabilitation coverage to HFrEF, were restricted to HF 
patients with chronic, stable disease.29–31 The largest of these, the NIH-funded HF-ACTION 
trial, excluded patients with ADHF and those within 6 weeks of hospital discharge.29 This 
prompted CMS to explicitly exclude recently hospitalized HF patients from cardiac 
rehabilitation coverage28 and an expert consensus recommendation for a period of stability 
of at least a month before enrolling HF patients in cardiac rehabilitation.32 HF-ACTION also 
enrolled relatively few older patients, particularly those with multiple comorbidities,33 who 
may be at increased risk for complications during cardiac rehabilitation.34 As noted above, 
physical impairments in older, frail patients with ADHF are broader, including deficits in 
balance and mobility, and far more severe than those observed in patients with chronic stable 
HF.20 Such deficits are not typically targeted by conventional, endurance-based cardiac 
rehabilitation.29 Addressing deficits in balance, mobility and functional strength may be 
important for preventing early injuries in frail, older ADHF patients and for enhancing gains 
in function.35, 36
We hypothesize that targeting physical frailty among older patients experiencing a HF 
hospitalization with a multi-domain structured physical rehabilitation intervention will 
improve physical function and reduce adverse outcomes. The current group of investigators 
completed a pilot study which showed that in older patients with ADHF, a structured 
intervention targeting physical function can improve the Short Physical Performance Battery 
(SPPB) score, a strong predictor of hospitalization, disability, and death.37 Based on these 
findings, the National Institute of Aging funded the Rehabilitation Therapy in Older Acute 
Heart Failure Patients (REHAB-HF) Trial to evaluate the efficacy of a novel, tailored, 
progressive, multi-domain, 12-week physical function intervention initiated during an 
ADHF hospitalization to improve physical function, as measured by SPPB (primary 
outcome), and reduce all-cause rehospitalization during the 6 months after initiation of the 
intervention.38
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Methods
Study Population
The REHAB-HF Trial has a target enrollment of 360 HF patients admitted for worsening 
heart failure (HF), based on at least one symptom of HF and at least two signs of HF and a 
change in medical treatment specifically targeting ADHF (Table 1). There is no left 
ventricular ejection fraction (EF) criterion. Patients must be at least 60 years of age or 
greater, performing basic activities of daily living prior to admission, able to walk at least 4 
meters at the time of enrollment (assistive device allowed) and expected to be discharged to 
home.
Patients are excluded if their HF is end-stage, defined as requiring or anticipating heart 
transplant or left ventricular assist device within the next 6 months or expected discharge on 
continuous intravenous ionotropic therapy. Patients with HF in the presence of severe 
primary valvular disease, such as severe aortic stenosis or mitral regurgitation, are excluded. 
Patients with advanced renal dysfunction who are currently requiring dialysis or at high risk 
for progressing to dialysis during the course of the study (defined as estimated glomerular 
filtration rate of < 20 mL/min/1.73 m2) are excluded due to concerns regarding ability to 
adhere to the study intervention. Similarly, patients are not enrolled if they have clinically 
evident dementia or significant impairment from a stroke, injury or other medical disorder 
that precludes participation in the intervention or following study protocol. Potential 
participants found to have mild cognitive impairment, common in older patients hospitalized 
with HF,20, 39 are eligible for enrollment provided there is adequate social support for 
adherence. Participants undergo screening for potential barriers to adherence using a 
standardized tool to assess personal commitment to adhering to the study requirements; 
degree of support from family members, caregivers and outpatient physicians; and potential 
transportation barriers. Those unable or unwilling to fully commit to all aspects of study 
participation or who lack support are considered high risk for non-adherence and are 
excluded from the study.
Eligible patients who provide informed consent and complete baseline testing successfully 
(Table 2) are randomized to attention control or to the multi-domain rehabilitation 
intervention. Block randomization is employed and stratified on clinical center and EF 
category (<45, ≥45). All sites use the same allocation process housed in the Coordinating 
Center (Wake Forest) database (REDCap) to ensure uniform randomization.
The REHAB-HF trial is being conducted in accordance with the Declaration of Helsinki and 
has been approved by Institutional Review Boards of all participating institutions. All study 
participants provide informed written consent. The REHAB-HF trial is registered with 
Clinicaltrials.gov (NCT02196038).
Attention Control
The usual care arm of REHAB-HF is defined as attention control due to increased 
surveillance of these participants in an effort to reduce the potential bias created from 
increased interactions of intervention participants with study personnel. Participants in the 
attention control group will receive at least bi-weekly contact from study personnel (nurses 
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or exercise physiologists) by phone or by specified study visits (weeks 4 and 12) during the 
first 3 months following the index hospitalization. Information regarding symptoms, HF 
transitional management program use, medical compliance, activity level, rehabilitation 
received, medical resource utilization, QOL and clinical events will be collected at each of 
these encounters. Participants in the attention control arm will not receive any specific 
rehabilitation recommendations or exercise prescription from study personnel. Adherence to 
medication regimens and follow-up appointments is encouraged.
Participants in both arms receive standard therapies as directed by their clinical providers, 
which may include any of the following services: inpatient physical therapy, outpatient 
physical therapy, or cardiac rehabilitation 6 weeks after discharge. All aspects of disease 
management, including medical therapy and HF management, are left to the discretion of the 
participant’s treating physician and are specifically not addressed by the study protocol for 
either study arm. Clinical concerns raised by the participant and/or identified by study 
personnel are referred to the participant’s health care provider(s) for further management.
REHAB-HF Intervention
The multi-domain rehabilitation intervention for this study is a novel integration of 
rehabilitation therapies developed specifically for older HF patients who have been 
hospitalized for ADHF. The goal of the intervention is to improve balance, mobility, strength 
and endurance utilizing reproducible, targeted exercises administered by a multi-disciplinary 
team with specific milestones for progression. The intervention is limited to physical 
rehabilitation and specifically does not address other aspects of disease management or 
frailty.
Frequency and Duration—The majority of the study interventions are facility-based in 
the outpatient setting. These 3 times per week sessions are initiated as soon as possible 
following hospital discharge, last approximately 60 minutes, and continue for 12 weeks or 
36 sessions. For participants with especially low functional performance, a limited number 
of these sessions may be conducted at home early following discharge (weeks 1–2). When 
feasible, daily sessions of approximately 30 minutes are conducted in the hospital prior to 
discharge.
Intensity—Exercise intensity is based upon patient-reported rate of perceived exertion 
(RPE) using a 6–20 point scale. During the first two weeks, target intensity is low (RPE ≤ 
12). In the outpatient setting, target RPE is gradually increased to 13 (“somewhat hard”) 
(range of 11–15) for endurance training and 15–16 for strength rehabilitation, as this level of 
intensity may be necessary to obtain significant functional improvement in strength.40 After 
4 weeks of the endurance intervention, intensity within the target RPE range can be adjusted 
to ensure a heart rate response of ≥20 beats per minute above the resting heart rate. This is 
typically needed to achieve >60% of exercise reserve capacity41 and is intended to ensure an 
adequate training effect to minimize non-responders while maintaining safety.29, 42, 43
Mode—Each session includes a warm-up, one-on-one targeted rehabilitation training in 
each domain (balance, mobility, strength and endurance), and a cool-down. At the beginning 
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of the intervention, participants undergo standardized stratification of functional 
performance in each of four domains: balance, strength, endurance and mobility (Table 3). 
We anticipate a range of initial performance levels based on the REHAB-HF pilot study, 
where 40% of participants were initially at the lowest level of functioning (level 1) for most 
domains, 33% were at level 2, and 27% were at level 3.20 Exercises specifically targeted to 
the participant’s functional level in each domain are then selected from the intervention 
protocols (see Table 4 for examples).
The relative time spent on each domain during the rehabilitation session is also tailored to 
the participant’s physical impairments (Figure). For example, a participant with poor 
balance and functional mobility spends a greater proportion of time performing exercises 
focused in these areas. Alternatively, a participant with only modest impairments in balance 
and functional mobility spends most of the exercise session performing endurance and 
strengthening exercises.
Progression—Progression is a key aspect of the study intervention. Participants are 
continually challenged to improve physical function by advancing through a structured, 
gradual progression using specific small increments in each exercise. Progression is based 
on performance during one-on-one training sessions and standardized re-assessment of 
functional performance in each domain conducted every 2 weeks (Table 3 and 4).
Safety—Pre-specified safety protocols based on vital signs and reported symptoms will be 
followed. Should a participant report a significant change in health status before or during 
exercise that presents a safety risk for continued exercise participation, a study physician 
onsite or the participant’s primary doctor will be consulted prior to exercise participation. 
Vital signs, including heart rate, blood pressure and pulse oximetery will be recorded at the 
beginning and conclusion of each session. Routine assessment of heart rate and RPE during 
the exercise session will also be used to enhance exercise safety. Exercising blood pressure 
and pulse oximetery will be monitored on a symptom-driven basis. Telemetry monitoring is 
not performed.
Intervention fidelity—Several strategies are used to promote consistent implementation 
of the intervention. These include: 1) a standardized protocol with a) specific rehabilitation 
exercises for each of the 4 domains; b) selection of initial exercises and progression based on 
standardized assessments (Table 3); c) detailed progression in small increments for each 
exercise; 2) training comprised of a) full day of in-person training of the study 
interventionists (experienced exercise physiologists and physical therapists) prior to study 
launch, including protocol review, demonstration videos using patient volunteers and hands-
on practice sessions; b) interactive study-wide webinars conducted at least annually; 3) 
continued monitoring to identify and address challenges related to fidelity. This includes 
tracking of exercises performed during each intervention session through a study-wide 
database. These reports are reviewed and discussed during bi-weekly teleconferences of 
study leadership for each participant actively engaged in the study physical rehabilitation 
intervention. The intervention supervisor at each site also reviews the implementation of the 
study intervention for each participant with the treating interventionist, addressing any 
challenges that arise.
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Home exercise—All participants randomized to the study intervention receive one home 
evaluation by study personnel following hospital discharge lasting approximately 30–45 
minutes. The purpose of the home visit is to identify areas for safe performance of the home 
exercise prescription. Participants are instructed in low-intensity walking at their usual pace, 
gradually increasing toward a goal of 30 minutes daily. Functional strengthening exercises 
(e.g. sit-to-stand from chair, step-ups, if feasible, and calf raises) are incorporated and 
customized based on patient goals and identified deficits. This brief home exercise program 
is to be performed on non-program days at least twice per week. Whenever possible, study 
personnel attempt to engage the participant’s caregivers/family to support home exercise.
Maintenance—Following the completion of the outpatient intervention, an individualized 
maintenance exercise prescription is developed by the interventionist based on the 
participant’s performance at the end of the 12-week supervised training intervention. 
Participants in the intervention arm will receive phone calls at months 4, 5, and 6, to discuss 
adherence to the exercise prescription and to gather information regarding study endpoints 
(Table 2). Physical activity is also monitored by accelerometers worn by participants in both 
study arms. These accelerometers are for monitoring only and do not have a display visible 
to the participant.
Retention and Adherence
Retaining participants with a high disease burden in a study that involves a significant 
commitment is expected to be challenging. The study addresses retention prior to enrollment 
by carefully explaining the commitment, identifying and addressing potential barriers, 
particularly if a participant is randomized to the intervention arm, and having the participant 
sign a behavioral agreement that details the requirements of the study. Adherence screening 
confirming participant commitment and support by family or caregivers and personal 
physicians is conducted prior to randomization. Participants unable to fully commit during 
this screening will not be randomized. Once randomized, the study will provide a clear 
schedule of all visits, reminders, same-day phone calls for any missed visits, involvement of 
family and caregivers, and sharing of test results and intervention progress, if applicable. 
Transportation support will also be available.
Interruptions to the study intervention, including illness and hospitalization, are anticipated. 
To help ensure each participant has a reasonable opportunity to complete the study 
intervention and that the physical performance outcome measures reflect the intended 
intervention of this study, limited extensions (2–4 weeks) are included in the study protocol 
for participants in both study arms.
Our primary measure of adherence is the percent of prescribed sessions attended. We will be 
able to assess this and other aspects of exercise adherence through tracking of sessions 
attended, sessions missed, reasons for missed sessions, as well as exercise performed in each 
session attended.
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Outcomes
The primary aim of the study is to assess the efficacy of the REHAB-HF intervention on 
physical function measured by the change in total SPPB score from baseline to 3 months. 
This and other study measures are obtained by independent, trained assessors who are 
blinded to participant’s intervention allocation. The SPPB measures physical function using 
3 components: usual gait speed over 4 meters, time to complete 5 chair rises, and standing 
balance with progressively narrow base of support. Each component is scored on a 0–4 scale 
and summed for an overall score range of 0–12.44 The SPPB was chosen as the primary 
outcome because it is a well-accepted, standardized, reliable, validated measure of physical 
function in the older population that can be collected safely and easily in clinic, home, and 
hospital settings, including in older patients hospitalized with ADHF.20, 25 The overall SPPB 
score and components are highly predictive of important clinical outcomes, including 
disability, hospitalization, nursing home admission, and death.44–46 The SPPB is sensitive to 
change in health status47 and responsive to exercise training.48–50 Interventions that improve 
SPPB also improve clinical events.48 A clinically meaningful but small change in SPPB 
score is 0.5 units and a substantial change is 1.0 units.50
Six-month all-cause rehospitalization was chosen as the key secondary outcome because: it 
is the most frequent adverse outcome in ADHF; it is associated with impaired physical 
function, reduced quality of life, increased mortality, and increased cost; and our pilot data 
and others’ suggest that it is responsive to physical function interventions.37 A 
rehospitalization is defined as a hospital stay >24 hours, including prolonged emergency 
department visits or observational unit stays, for any cause. For exploratory analyses and 
safety monitoring, rehospitalizations will be categorized by the site investigators as primarily 
due to non-cardiovascular, HF, or other cardiovascular (myocardial infarction, acute 
coronary syndrome without myocardial infarction, arrhythmia, peripheral vascular) cause, 
and whether they were related to the study intervention or assessments.
Additional exploratory analyses will examine the effect of the intervention on: the 
components of the SPPB; 6-minute walk distance; QOL (both HF-specific and global); 
frailty phenotype as originally described by Fried;51, 52 depression; cognitive function; all-
cause combined rehospitalization and death; global rank endpoint of SPPB score, all-cause 
rehospitalization and death; HF-specific rehospitalizations; cardiovascular events; 
rehospitalization days; facility-free days; deaths; falls; and biomarkers. Sub-group analyses 
based on EF category (<45, ≥45) are also planned.
Statistical Analysis and Sample Size
The effect of the intervention on SPPB score measured 3 months post-randomization will be 
estimated and tested for significance using analysis of covariance, where the randomized 
arm is the between-subject grouping variable and the pre-randomized measure of SPPB 
score, clinical site, age, gender, and EF category (<45, ≥45) will be covariates. Least square 
means will be used to estimate the intervention effect. Tests will be conducted at the 5% 
two-sided level of significance.
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The secondary aim of the study is to assess the intervention’s effect on the total number of 
all-cause rehospitalizations during the 6 months following discharge from the index 
hospitalization. Since the count of all-cause rehospitalizations per participant may not be 
normally distributed, the effect of the intervention on total all-cause rehospitalizations will 
be estimated using a Poisson model for modeling count data, where the randomized arm is 
the between-subject grouping variable and clinical site, age, gender, and EF category will be 
covariates. A supplemental analysis will be performed adding the duration of the index 
hospitalization and the number of inpatient intervention sessions as additional covariates. To 
account for the expected dropouts or non-compliance with the intervention, we will 
incorporate compliance (“on treatment”) as collected by adherence measurements. Simple 
observational treatment comparisons that include only patients who complied with specified 
levels of the intervention protocol will be examined as supportive information, recognizing 
the limitations of such comparisons.
The REHAB-HF pilot study showed an estimated intervention effect of an increase of 1.13 
units in 3-month SPPB score (the primary outcome) or a 17.9% relative increase above the 
least square mean for the attention control group, with a mean square error from the analysis 
of covariance model of 3.269.37 This study is designed to have 80% power to detect a 10% 
treatment difference (0.63 absolute difference) in the 3-month least square mean of SPPB 
score. Based on the findings of the REHAB-HF pilot study, this requires 258 evaluable 
participants. Assuming an 85% retention rate, the study requires randomizing 304 
participants (25.3 per site per year).
In the completed pilot study, the number of all-cause rehospitalizations within 6 months was 
reduced 29.3% by the intervention (1.673±0.392 per patient in the attention control group 
vs. 1.157±0.349 in the intervention group). We performed additional work with an analysis 
of a contemporaneous sample of 239 consecutive patients aged ≥ 65 years admitted with the 
primary diagnosis of ADHF. This confirmatory sample yielded a 6-month rehospitalization 
event rate estimate within 0.5% of our attention control group, giving confidence in our pilot 
study estimate. This study is designed to have 80% power to detect a 25% reduction (0.41 
absolute difference) in the total number of all-cause rehospitalizations during the 6 months 
following the index hospitalization. This requires 334 participants; assuming loss to follow-
up of 5%, the study requires randomizing 352 total participants. Rounding up, this study will 
randomize a total of 360 patients, providing > 80% power for the primary and secondary 
aims.
Economic analysis
Patient-level information on medical resource use, patient time spent on rehabilitation-
related activities and QOL, as measured with the EuroQol 5-Dimension 5-Level 
(EQ-5D-5L), is collected throughout the 6-month follow-up period (Table 2). 
Interventionists and support staff will provide supplemental information to estimate costs to 
provide the rehabilitation intervention. These data will be used to estimate direct medical 
costs, non-direct medical costs, indirect (patient time) costs and quality-adjusted survival. 
Mean costs and quality-adjusted survival over the six-month follow-up period in the 
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REHAB-HF will be compared between patients randomized to the rehabilitation 
intervention versus attention control.
If the intervention does not produce a net cost-savings in the short-term, a long-term cost-
effectiveness analysis will be performed to assess the incremental costs of the intervention 
versus the incremental impact of the intervention on quality-adjusted survival. The 
previously-developed and validated TEAM-HF Cost-Effectiveness Model53 will be used to 
generate longer-term estimates of costs, survival and quality-adjusted survival. The 
economic evaluation of the REHAB-HF intervention will be used to propose payment 
models for third-party payers (e.g. CMS) and accountable care organizations and health 
maintenance organizations who provide care to HF patients on a capitated basis.
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Discussion
REHAB-HF is a multicenter, prospective randomized controlled trial designed to determine 
if a tailored, structured, progressive multi-domain physical rehabilitation intervention 
addressing deficits in balance, mobility, strength, and endurance, improves physical function 
and reduces rehospitalizations compared to attention control in older patients hospitalized 
with ADHF. This is the first HF clinical trial to employ a multi-domain physical 
rehabilitation intervention beginning during ADHF hospitalization and transitioning to the 
outpatient setting. REHAB-HF is designed to address multiple high-priority gaps in the 
evidence regarding exercise training in HF patients, including those with markedly reduced 
physical function who are unable to undertake traditional exercise training, > 60 years, with 
multiple co-morbidities, who are women, and who have HF with preserved EF 
(HFpEF).37, 54, 55 The trial has consistently met enrollment targets with 160 of 360 
participants enrolled to date and study completion anticipated in 2019.
We have incorporated several novel features into our study design to meet the specific needs 
of older, frail recently hospitalized HF patients that distinguishes REHAB-HF from 
prior29, 30 and ongoing56–58 investigations of exercise training in HF. During our pilot study, 
we observed unexpectedly severe impairments in all functional domains, including balance 
and mobility.20 Prior studies have shown that not identifying and correcting balance 
impairments early during rehabilitation can lead to increased injuries.36 In response to this 
and in an effort to maximize training response while minimizing the risk of injuries and 
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falls, we provide one-on-one training to deliver an individually tailored, multi-domain 
intervention with an early emphasis on addressing deficits in balance, mobility and 
functional strength.34, 59 Progressively more endurance training is incorporated as balance, 
mobility and strength improve (Figure). The timing of the REHAB-HF intervention is also 
unique in that it is initiated as early as the time of hospitalization following initial 
stabilization of ADHF. The study intervention is also highly adaptable to a wide range of 
functional impairments while promoting gradual, structured progression and maintaining 
fidelity.
We hypothesize that the widespread, severe functional impairments targeted by our 
intervention are largely due to skeletal muscle dysfunction as a result of the systemic effects 
of the HF clinical syndrome, medical comorbidities, aging, acute illness and hospital-related 
immobility.16, 55 Given the systemic nature of these mechanisms, we expect the intervention 
will have similar efficacy in older frail patients recovering from ADHF regardless of EF. 
This is supported by several observations. Older patients with chronic HFpEF and HFrEF 
have similar functional impairments with similar underlying skeletal muscle abnormalities, 
including shift in fiber types, reduced capillary density, and impaired mitochondrial 
function.17, 60–63 During ADHF, patients with both types of HF are subject to acute muscle 
loss and dysfunction associated with hospitalization and immobility.64–67 In our pilot, the 
nature and severity of functional impairments in older patients with ADHF were 
independent of EF.20 The similarities in functional impairments and their proposed 
mechanisms may also help explain the remarkably similar vulnerability to adverse clinical 
outcomes, frequently due to non-cardiac causes, observed in older patients following a HF 
hospitalization across the spectrum of EF.3 In fact, many of the proposed contributing factors 
to functional impairments and clinical outcomes, such as aging, comorbidities and acute 
immobility, are common to a broader population of older, frail hospitalized patients at risk 
for the “post-hospital syndrome”,24 supporting the potential further generalizability of study 
findings.
While the focus of the study is on addressing physical function impairments, descriptors of 
impairments common in acutely ill, older patients (e.g. frailty, falls, cognition, urinary 
incontinence) will also be captured. Such syndromes are by nature non-disease specific and 
are not typically targeted by HF management strategies. However, they may be associated 
with HF, worsened as components of the post-hospital syndrome,24 can complicate HF 
management and contribute to adverse clinical outcomes in older patients with HF. The 
frequency and severity of these geriatric syndromes will be tracked over the course of the 
study, and the contribution to QOL, economic and clinical outcomes during the high risk 
period following ADHF hospitalization will be assessed. Such insights could help inform the 
design of complimentary novel interventions.
In conclusion, REHAB-HF is a multi-center randomized control trial that will address key 
evidence gaps by determining if a novel physical rehabilitation intervention will improve 
physical function and reduce all-cause rehospitalizations following an ADHF hospitalization 
in older, frail patients with multiple comorbidities and severe impairments in physical 
function. The trial results could have a major impact on the management of older patients 
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with ADHF by improving the morbidity, reduced quality-of-life, and high health care costs 
associated with the nearly 1 million rehospitalizations annually in older HF patients.68
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Figure 1. 
Approximate percent of exercise time in each physical function domain based on functional 
level.
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Table 1
REHAB-HF Inclusion and Exclusion Criteria
Inclusion Criteria
Patients eligible for the trial must meet the following criteria at randomization:
• Age ≥ 60 years old
• In the hospital setting >24 hours for the management of ADHF, defined as:
– At least one symptom of HF which has worsened from baseline:
♦ Dyspnea at rest or with exertion
♦ Exertional fatigue
♦ Orthopnea
♦ Paroxysmal nocturnal dyspnea (PND)
– At least two of the signs of HF
♦ Pulmonary congestion or edema on exam (rales) or by chest x-ray
♦ Elevated jugular venous pressure or central venous pressure ≥ 10 mm Hg
♦ Peripheral edema
♦ Wedge or left ventricular end diastolic pressure ≥15 mmHg
♦ Rapid weight gain (≥ 5 lbs.)
♦ Increased b-type natriuretic peptide (BNP) (≥100 pg/ml) or N-terminal prohormone BNP (≥220pg/ml)
– Change in medical treatment specifically targeting HF defined as change in dose or initiation of or augmentation of at 
least one of the following therapies
♦ Diuretics
♦ Vasodilators
♦ Inotropes (including digoxin if for HF)
♦ Other neurohormonal modulating agents, including angiotensin converting enzyme inhibitors, angiotensin 
II receptor blockers, beta-blockers, aldosterone or direct renin inhibitors
• Clinical stability to allow participation in study assessments and the intervention
• Prior to admission, patient was independent with basic activities of daily living (ADLs) including the ability to ambulate 
independently (with or without the use of an assistive device)
• Able to walk 4 meters (with or without the use of an assistive device) at the time of enrollment
Exclusion Criteria
At the time of randomization, none of the following conditions may exist:
• Acute myocardial infarction based on clinical diagnosis
• Requiring care in an intensive care unit
• Planned discharge other than to where the participant will live independently
• Dementia that precludes ability to participate in rehabilitation and follow study protocols
• Impairment from stroke, injury or other medical disorder that precludes participation in the intervention
• Advanced chronic kidney disease (eGFR < 20 mL/min/1.73 m2) or dialysis
• Prior cardiac transplantation or planned within the next 6 months
• Expected use of continuous intravenous inotropic therapy after discharge
• Ventricular assist device or anticipated within the next 6 months
• Severe aortic valve stenosis
• Already actively participating in facility-based cardiac rehabilitation
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Inclusion Criteria
• Anticipated hospital discharge before baseline study measures could be completed
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Table 3
Performance Levels for Strength, Balance, Mobility and Endurance
Level 1 Level 2 Level 3 Level 4
Strength: Rise from chair
without hand support unable at least once
5 times in > 15
but <60 seconds
5 times in ≤
15 seconds
Balance: Standing
unable with feet
together for 10
seconds
with feet together
for 10 seconds
unsupported and
reach forward 10
inches
on 1 leg for
10 seconds
Endurance: Continuous
walking < 2 minutes
≥ 2 but < 10
minutes
≥ 10 but
< 20 minutes ≥ 20 minutes
Mobility: Gait speed ≤ 0.4 m/s > 0.4 but ≤ 0.6 m/s > 0.6 but ≤ 0.8 m/s > 0.8 m/s
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Table 4
Examples of Exercise Prescription by Performance Levels for each exercise domain: Strength, Balance, 
Mobility and Endurance
Exercise
Examples by
Domain
Level 1 Level 2 Level 3 Level 4
Strength
a) Sit to stand
b) Step-ups (front
and side)
On edge of chair
leaning forward and
pushing with hands
4 inch step*
On edge of chair
leaning forward with
arms reaching out
6 inch step*
In back of chair
with arms across
chest
8 inch step*
As in Level 3 at
faster pace or from
lower surface
10 inch step and/or
with resistance*
Balance
Stand and reach
Stand with feet
shoulder width
apart; reach forward
6 inches and hold.
Stand with feet
shoulder width
apart; reach
forward 10 inches
and hold.
Stand with feet
together; reach
forward 6 inches
(progressing to 10
inches) and hold
Semi-tandem
stance; reach
forward 6 inches
(progressing to 10
inches) and hold
Endurance:
Continuous
walking
Repeated brief
bouts for a total
duration of 10
minutes
Repeated brief
bouts for a total
duration of 20
minutes
Repeated bouts for
a total duration of
30 minutes
Continuous for 20-
30 minutes
Mobility
Gait training
Stop and start
abruptly
Brief accelerations
during walking
Quick change of
direction
Quick change of
direction while
engaged in activity
requiring cognitive
attention (e.g.
conversation,
questioning)
Frequency and duration: Outpatient 3x/week for approximately 60 minute sessions integrating all domains (goal 36 sessions). Inpatient: 30 minute 
sessions daily until discharge with focus on domains to preserve functional mobility (when feasible; typically 0–2 sessions).
Intensity: RPE <12 initially; increasing to 13 (11–15) for endurance; 15–16 for strength. Balance and mobility not to exceed endurance RPE.
Mode: Exercises appropriate to a participant’s performance level in each domain (Table 3) are selected as illustrated in the examples above.
Progression: As performance improves, participants advance to slightly more challenging exercises through structured, small increments. 
Performance is assessed during one-on-one training sessions, including standardized re-assessment of functional performance in each domain 
(Table 3) conducted every 2 weeks.
*
Performed with support of two hands, support of one hand, or no hand support.
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